ASO Author Reflections: Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection.
0/5 보강
APA
Sumiyoshi S, Kubota T, Shiozaki A (2026). ASO Author Reflections: Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection.. Annals of surgical oncology, 33(1), 315-316. https://doi.org/10.1245/s10434-025-18398-z
MLA
Sumiyoshi S, et al.. "ASO Author Reflections: Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection.." Annals of surgical oncology, vol. 33, no. 1, 2026, pp. 315-316.
PMID
40982151
같은 제1저자의 인용 많은 논문 (5)
- Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review.
- ASO Visual Abstract: Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection-A Multicenter Cohort Study.
- Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection: A Multicenter Cohort Study.
- No regional survival disparities following curative gastrectomy in patients aged over 80 years with gastric cancer. a multicenter retrospective study.
- Prostate cancer presenting as brain metastasis with concurrent elevation of carcinoembryonic antigen and carbohydrate antigen 19-9 levels: illustrative case.